Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 13/1/2021
SIETES contiene 93213 citas

 
 
 1 a 20 de 155 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M, Strong M, Selby P, Gittoes N. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess 2016;20:1-406. [Ref.ID 101044]
3. Cita con resumen
Ghinea N, Lipworth W, Kerridge I. Propaganda or the cost of innovation? Challenging the high price of new drugs. BMJ 2016;352:i1284. [Ref.ID 100333]
6.Tiene citas relacionadas Cita con resumen
Kmietowicz Z. NICE rejects trastuzumab emtansine for use on NHS. BMJ 2015;351:h6837. [Ref.ID 99764]
7. Cita con resumen
Maynard A, Bloor K. Regulation of the pharmaceutical industry: promoting health or protecting wealth?. J R Soc Med 2015;108:220-2. [Ref.ID 99099]
8. Cita con resumen
Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, Avorn J, Choudhry NK. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015;162:407-19. [Ref.ID 98960]
9. Cita con resumen
Chinthapalli K. NICE is dead; long live NICE. BMJ 2013;346:16. [Ref.ID 95480]
10. Cita con resumen
Anónimo. An introduction to the method of cost-effectiveness analysis. Drug Ther Bull 2012;50:81-4. [Ref.ID 93356]
11.Tiene citas relacionadas Cita con resumen
Raftery J, Chorozoglou M. Possible net harms of breast cancer screening: updated modelling of Forrest report. BMJ 2012;344:14. [Ref.ID 92216]
13.Tiene citas relacionadas
Gage BF. Cost of dabigatran for atrial fibrillation. BMJ 2011;343:915-6. [Ref.ID 91803]
14. Cita con resumen
Noyes K, Bajorska A, Chappel A, Schwid SR, Mehta LR, Weinstock-Guttman B, Holloway RG, Dick AW. Cost-effectiveness of disease-modifying therapy for multiple sclerosis. A population-based study. Neurology 2011;77:355-63. [Ref.ID 90812]
15.
Nayak S, Roberts MS, Greenspan SL. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med 2011;155:751-61. [Ref.ID 90509]
16. Cita con resumen
Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:1-11. [Ref.ID 90077]
17. Cita con resumen
John-Baptiste A, Bell C. Industry sponsored bias in cost effectiveness analyses. BMJ 2011;342:4-5. [Ref.ID 89996]
18. Cita con resumen
Anónimo. A guide to health economic evaluations. Drug Ther Bull 2010;48:105-8. [Ref.ID 89279]
19.
Duerden M. From a cancer drug fund to value based pricing of drugs. BMJ 2010;341:412-3. [Ref.ID 89253]
20. Cita con resumen
Wise J. NICE approved 80% of drugs it evaluated in past decade. BMJ 2010;341:168. [Ref.ID 88927]
Seleccionar todas
 
 1 a 20 de 155 siguiente >>